Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Anthera Pharmaceuticals
(OTCEM:ANTH)
Intraday
$~0
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$~0
0
[0.00%]
Last update: 3:50PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Anthera Pharmaceuticals Stock (OTC:ANTH)
Anthera Pharmaceuticals Stock (OTC: ANTH)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 05, 2020
'Trading Nation' Analysts Give Their Health Care Picks
Craig Jones
-
Nov 5, 2020, 4:47PM
Tuesday, March 24, 2020
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Mar 24, 2020, 11:39AM
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
-
Mar 24, 2020, 11:35AM
Friday, December 13, 2019
Stocks That Hit 52-Week Lows On Friday
Lisa Levin
-
Dec 13, 2019, 12:22PM
Wednesday, January 30, 2019
Anthem Raises Quarterly Dividend From $0.75 To $0.80/Share
Benzinga Newsdesk
-
Jan 30, 2019, 6:17AM
Thursday, June 28, 2018
Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut
Benzinga
-
Jun 28, 2018, 8:26AM
Wednesday, June 27, 2018
Anthera Pharma Reports Withdrawal Of Nasdaq's Hearing Request; Trading In Issue Will Be Suspended On Jun. 28, 2018
Benzinga
-
Jun 27, 2018, 8:14AM
Friday, May 25, 2018
Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended
Benzinga
-
May 25, 2018, 9:19AM
Friday, May 18, 2018
Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
Benzinga
-
May 18, 2018, 8:00AM
Thursday, May 17, 2018
Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
Benzinga
-
May 17, 2018, 8:27AM
Monday, April 16, 2018
UPDATE: Anthera Pharma Says Plans To Eliminate Non-Essential Salaried Positions Between Apr. 15-30; Sees Recording Exit Charges ~$1.2M Related To Restructuring
Benzinga
-
Apr 16, 2018, 5:30PM
Anthera Pharma 8-K Shows Board Approved, Commenced Mgmt., Admin. Personnel Reorganization
Benzinga
-
Apr 16, 2018, 5:30PM
Monday, March 26, 2018
17 Stocks Moving In Monday's Pre-Market Session
Benzinga
-
Mar 26, 2018, 8:06AM
Friday, March 16, 2018
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
Benzinga
-
Mar 16, 2018, 2:33PM
Tuesday, March 13, 2018
Benzinga Pro's Top 10 Most-Searched Tickers On Tues., Mar. 13
Benzinga
-
Mar 13, 2018, 9:30AM
46 Biggest Movers From Yesterday
Benzinga
-
Mar 13, 2018, 5:38AM
Monday, March 12, 2018
Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge
Benzinga
-
Mar 12, 2018, 2:33PM
32 Stocks Moving In Monday's Mid-Day Session
Benzinga
-
Mar 12, 2018, 12:58PM
Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher
Benzinga
-
Mar 12, 2018, 12:14PM
Mid-Morning Market Update: Markets Open Higher; Lumentum To Acquire Oclaro For $9.99/Share
Benzinga
-
Mar 12, 2018, 10:12AM
Anthera Pharmaceuticals Shares Down 81.9% Following Announcement That Co. Would Terminate Development Of Sollpura After Phase 3 Study Did Did Not Achieve Primary Endpoint
Benzinga
-
Mar 12, 2018, 9:36AM
Anthera Pharma's Phase 3 Study of Sollpura Did Not Achieve its Primary Endpoint, Further Development to be Discontinued
Benzinga
-
Mar 12, 2018, 8:01AM
Anthera Phamra Halted, News Pending
Benzinga
-
Mar 12, 2018, 7:56AM
Tuesday, March 06, 2018
Anthera Pharma S-3 Shows Registration For $100M Mixed Securities Shelf Offering
Benzinga
-
Mar 6, 2018, 5:34PM
Monday, March 05, 2018
Anthera Pharmaceuticals Reports Q4 EPS $(0.73) vs $(0.66) Est.
Benzinga
-
Mar 5, 2018, 4:08PM
Thursday, February 22, 2018
41 Biggest Movers From Yesterday
Benzinga
-
Feb 22, 2018, 5:13AM
Wednesday, February 21, 2018
Mid-Afternoon Market Update: Hackett Group Rises On Upbeat Earnings; QTS Realty Trust Shares Plunge
Benzinga
-
Feb 21, 2018, 2:31PM
34 Stocks Moving In Wednesday's Mid-Day Session
Benzinga
-
Feb 21, 2018, 12:34PM
Mid-Day Market Update: Dow Gains Over 100 Points; Tile Shop Shares Fall On Earnings Miss
Benzinga
-
Feb 21, 2018, 12:01PM
Anthera Pharmaceuticals Shares Up 37.3% As Roth Capital Initiated Coverage With Buy Rating And $10.00 Price Target; BZ NOTE: Price Target Represents Nearly 500% Possible Price Appreciation From Where Stock Closed Tues.
Benzinga
-
Feb 21, 2018, 11:27AM
Benzinga's Top Upgrades, Downgrades For February 21, 2018
Benzinga
-
Feb 21, 2018, 9:31AM
Roth Capital Initiates Coverage On Anthera Pharmaceuticals with Buy Rating, Announces $10.00 Price Target
Benzinga
-
Feb 21, 2018, 7:58AM
Thursday, February 15, 2018
22 Stocks Moving In Thursday's Pre-Market Session
Benzinga
-
Feb 15, 2018, 8:41AM
Monday, February 05, 2018
Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura
Benzinga
-
Feb 5, 2018, 8:32AM
Monday, January 22, 2018
Anthera Announces a 'Positive' Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter
Benzinga
-
Jan 22, 2018, 8:33AM
Monday, December 11, 2017
Anthera Pharma Offers Outcome Of Interim Futility Analysis In Phase 3 RESULT Trial Of Sollpura: 'study allows for more frequent and higher dose adjustments based upon clinical signs and symptoms than the previous Phase 3 SOLUTION study'
Benzinga
-
Dec 11, 2017, 8:39AM
Tuesday, November 21, 2017
35 Biggest Movers From Yesterday
Benzinga
-
Nov 21, 2017, 5:10AM
Monday, November 20, 2017
34 Stocks Moving In Monday's Mid-Day Session
Benzinga
-
Nov 20, 2017, 12:30PM
Monday, November 13, 2017
Anthera Pharmaceuticals Files For $50,073,580M Common Stock Offering
Benzinga
-
Nov 13, 2017, 5:29PM
Monday, November 06, 2017
Anthera Pharmaceuticals Reports Q3 EPS $(0.58) vs $(0.91) Est.
Benzinga
-
Nov 6, 2017, 8:35AM
Tuesday, October 24, 2017
35 Stocks Moving In Tuesday's Mid-Day Session
Benzinga
-
Oct 24, 2017, 12:50PM
Anthera Pharma Prices ~2.307M Share Offering At $1.25/Share; Warrants For 3 Added Shares Will Have Exercise Price Of $1.55/Share
Benzinga
-
Oct 24, 2017, 8:31AM
Thursday, September 07, 2017
Anthera Pharma Reports Surpassed 50% Milestone For Screening Of Patients In RESULT Phase 3 Study Of Sollpura In CF
Benzinga
-
Sep 7, 2017, 8:34AM
Monday, August 28, 2017
Anthera Reports Top Line Final Data from the Extension Period of the Phase 2 BRIGHT-SC Study
Benzinga
-
Aug 28, 2017, 8:32AM
Monday, August 14, 2017
Anthera Pharma Reports RESULT Phase 3 Study Of Sollpura Will Be Included In European CF Trial Network
Benzinga
-
Aug 14, 2017, 8:31AM
Wednesday, August 09, 2017
Anthera Reports FDA Orphan Drug Designation For Blisibimod For Treatment Of IgA Nephropathy
Benzinga
-
Aug 9, 2017, 4:00PM
Anthera Pharma Reports Q2 EPS $0.03 vs $(2.79) In Same Qtr. Last Year
Benzinga
-
Aug 9, 2017, 8:33AM
Monday, July 10, 2017
Anthera Pharmaceuticals Reports Phase 3 Sollpura Clinical Study Will Be Included In Cystic Fibrosis Foundation Therapeutics Development Network
Benzinga
-
Jul 10, 2017, 8:31AM
Thursday, July 06, 2017
Anthera Reports Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of Sollpura, Expects Top Line Data At End of 2017 or Early 2018
Benzinga
-
Jul 6, 2017, 8:32AM
Monday, May 15, 2017
Anthera Announces 1st Patient Screened In RESULT Pivotal Phase 3 Sollpura Study
Benzinga
-
May 15, 2017, 4:03PM
Show more